TissGeneSummary for LYZL2 |
Gene summary |
Basic gene information | Gene symbol | LYZL2 |
Gene name | lysozyme-like 2 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 10p11.23 | |
Type of gene | protein-coding | |
RefGenes | NM_183058.2, | |
Description | lysozyme 2lysozyme-2lysozyme-like protein 2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 612748 | |
HGNC : HGNC | ||
Ensembl : ENSG00000151033 | ||
HPRD : 14337 | ||
Vega : OTTHUMG00000017898 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_LYZL2 | |
BioGPS: 119180 | ||
Pathway | NCI Pathway Interaction Database: LYZL2 | |
KEGG: LYZL2 | ||
REACTOME: LYZL2 | ||
Pathway Commons: LYZL2 | ||
Context | iHOP: LYZL2 | |
ligand binding site mutation search in PubMed: LYZL2 | ||
UCL Cancer Institute: LYZL2 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of LYZL2 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for LYZL2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for LYZL2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for LYZL2 |
TissGeneSNV for LYZL2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.K13R | PCPG | 5 |
p.A29G | UVM | 2 |
p.D21N | SKCM | 1 |
p.K75T | STAD | 1 |
p.S101N | SKCM | 1 |
p.D186N | STAD | 1 |
p.R131H | DLBC | 1 |
p.R130I | LUAD | 1 |
p.H141R | HNSC | 1 |
p.K75E | BRCA | 1 |
p.T109M | HNSC | 1 |
p.A143T | UCEC | 1 |
p.K13R | UVM | 1 |
p.A97V | PRAD | 1 |
p.S145L | LUAD | 1 |
p.G132V | LUAD | 1 |
p.Q167K | LUAD | 1 |
p.N104K | THCA | 1 |
p.C71Y | LUAD | 1 |
p.L9V | LUSC | 1 |
p.S115R | LUAD | 1 |
p.N170I | SKCM | 1 |
p.E192* | CESC | 1 |
p.P5R | SKCM | 1 |
p.D190E | UCEC | 1 |
p.E165D | THYM | 1 |
p.G132* | LUAD | 1 |
p.H141L | LUSC | 1 |
p.A50V | UCEC | 1 |
p.R70P | HNSC | 1 |
p.W128* | UCEC | 1 |
p.R70H | STAD | 1 |
p.G132E | BLCA | 1 |
p.E165D | UCEC | 1 |
p.G87V | LUAD | 1 |
p.S7G | CESC | 1 |
p.W86R | LIHC | 1 |
p.H141N | LUAD | 1 |
p.M47I | LUSC | 1 |
p.L45F | STAD | 1 |
p.P11L | LUAD | 1 |
p.E192* | BLCA | 1 |
p.K160N | BLCA | 1 |
p.T166A | UCS | 1 |
p.G31V | LUAD | 1 |
p.M169I | BLCA | 1 |
Top |
TissGeneCNV for LYZL2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for LYZL2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
TCGAfusionPortal | PRADA | HNSC | TCGA-CV-7406-01A | FBXO28-LYZL2 | Out-of-frame | Chr1:224302098 | Chr10:30901829 |
Top |
TissGeneNet for LYZL2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for LYZL2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for LYZL2 |
TissGeneDrug for LYZL2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for LYZL2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0011334 | Dental caries | 2 | BeFree,GWASCAT |